Original Research
Published on 16 Dec 2025
An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany
in Health Economics
Frontiers in Public Health
doi 10.3389/fpubh.2025.1667315
- 1,303 views
